Cas:39537-99-0 Micinicate manufacturer & supplier

Chemical Name:Micinicate

CAS.NO:39537-99-0

Synonyms:Micinicat;Micinicatum;Micinicata;Micinicate;UNII-M87S131A7F;Micinicato;Nicotinoyl cyclandelate

Molecular Formula:C₂₃H₂₇NO₄

Molecular Weight:381.46500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:506.1ºC at 760mmHg

Density:1.16g/cm3

Index of Refraction:1.561

PSA:65.49000

Exact Mass:381.19400

LogP:4.73770

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Micinicat chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Nicotinoyl cyclandelate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Micinicatum Use and application,Micinicato technical grade,usp/ep/jp grade.

Related News: Here’s how Biogen did during the three months ended June 30 compared with what Wall Street expected, according to average estimates compiled by Refinitiv. (+-)-1-(Biphenyl-3-yloxy)-4-(3-pyridyl)-2-butanol oxalic acid salt manufacturers The company will see an immediate $6 billion bump to its topline thanks to Alexion’s C5 inhibitors, used to treat rare diseases like paroxysmal nocturnal hemoglobinuria. 3-(fluoromethyl)-1-methyl-N-(4-(2-phenylcyclopropyl)thiophen-3-yl)-1H-pyrazole-4-carboxamide suppliers The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually. 6-methyl-8-phenyl-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-g]isoquinoline vendor & factory McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019.,It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time.